VIVES Funds
VC Fund
Wavre, Belgium
VIVES Funds is a VC fund in Wavre focused on Biotechnology and Health Care. VIVES is a seed capital fund initiated by UCLouvain which invests in companies developing disruptive innovations with a positive societal impact.
- Total investments:
- 10
- Last investment:
- Lead investor:
- 20%
Last updated:
For AI agents: llms.txt
Industries VIVES Funds invests in
Stages VIVES Funds invests in
Countries VIVES Funds invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
3 more contacts available
Round size
- Seed
- $2.9M–$5.5M
- Series A
- $18M–$165M
- Series B
- $34M–$132M
Investment Focus
Industry
- Biotechnology 4 (40%)
- Health Care 3 (30%)
- Therapeutics 3 (30%)
- Medical 2 (20%)
- Medical Device 2 (20%)
Stage
- Series A 4 (40%)
- Seed 3 (30%)
- Series B 1 (10%)
- Funding Round 1 (10%)
Country
- Belgium 4 (40%)
- France 3 (30%)
- Switzerland 1 (10%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Sandra Schoors
Partner
|
Partner | Total investments: 2 | Find email | |
Yannick Vancoppenolle
Partner
|
Partner | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Bionyra
|
Bionyra Pharma is a clinical-stage biopharmaceutical startup developing next-generation biologics for serious immune-mediated inflammatory diseases. | $165M / Series A / Jun 22, 2026 | |
Nuclidium
|
NUCLIDIUM is a clinical-stage radiopharmaceutical company that develops novel radionuclide PET tracers for precision diagnostics. Using copper isotopes, Copper-61 for diagnostics and Copper-67 for therapeutics, the company is creating a differentiated platform with the potential to overcome existing limitations in radiotheranostics. | $33.6M / Series B / May 28, 2026 | |
Generare
|
Generare is a biotech startup that discovers next-generation medicines and high-value molecules hiding in soil bacteria. | $23.1M / Series A / Apr 02, 2026 | |
Sunrise
|
Sunrise aims to bring simple answers to millions of people suffering from sleep disorders.We have developed a 3-gram sensor to diagnose sleep with gold standard quality. The technology offers a revolutionary new way to measure brain commands at night, with published clinical results never seen before. Studies demonstrate Sunrise is as accurate asin-lab sleep studies, at a fraction of the cost.Affecting one in three people, sleep disorders are extremely common. Sleep apnea is the most prevalent disease with almost 1 billion persons concerned. This condition leads to great body damage over time and yet remains undiagnosed in 80% of the cases.Patients, caregiver and insurers stand to benefit greatly from a solution to current highly cumbersome, expensive and time-consuming diagnostics systems. | $29.2M / Sep 25, 2025 | |
|
Nuclidium
|
NUCLIDIUM is a clinical-stage radiopharmaceutical company that develops novel radionuclide PET tracers for precision diagnostics. Using copper isotopes, Copper-61 for diagnostics and Copper-67 for therapeutics, the company is creating a differentiated platform with the potential to overcome existing limitations in radiotheranostics. | $131.8M / Series B / Jul 10, 2025 | |
BiocSol
|
BiocSol focus on sustainable microbial-based crop protection. | $5.5M / Seed / Nov 20, 2024 | |
ATB Therapeutics
|
ATB Therapeutics is a biopharmaceutical company that provides novel therapeutic solutions and treatments for cancer patients. | $57.2M / Series A / Nov 18, 2024 | |
|
Generare
|
Generare is a biotech startup that discovers next-generation medicines and high-value molecules hiding in soil bacteria. | $5.5M / Seed / Oct 07, 2024 | |
|
Brightflow
|
Brightflow operates as a medical device startup. | $18.2M / Series A / Sep 10, 2024 | |
VOCSense
|
VOCSens spin-off is developing a new concept of an environmental camera, EnviCam®, allowing you to see the invisible, those chemical and biochemical molecules that surround us. The company has developed a manufacturing process, CMOSEnvi™, fully compatible with the CMOS technology found in everyday electronic chips. | $2.9M / Seed / Sep 24, 2021 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does VIVES Funds invest in?
VIVES Funds invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Seed stage. Most of the 10 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is VIVES Funds's check size?
VIVES Funds typically joins rounds of $2.9M–$5.5M at Seed, $18M–$165M at Series A and $34M–$132M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds VIVES Funds participates in.
How do I contact VIVES Funds?
Public channels for VIVES Funds include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at VIVES Funds?
The team at VIVES Funds includes Sandra Schoors (Partner) and Yannick Vancoppenolle (Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
